alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT
      32.1











CERTIFICATION
      PURSUANT TO


18
      U.S.C.
      SECTION 1350,


AS
      ADOPTED PURSUANT TO


SECTION
      906 OF THE SARBANES-OXLEY ACT OF 2002











In
      connection with the Quarterly Report of Tonga Capital Corporation (the
      "Company") on Form 10-QSB for the period ending March 31, 2007 as filed with
      the
      Securities and Exchange Commission on the date hereof (the "Report"). I, Barent
      W. Cater, President and Chief Executive Officer of the company, certify,
      pursuant to 18 USC Section 1350, as adopted pursuant to Section 906 of the
      Sarbanes-Oxley Act of 2002, that to the best of my knowledge and
      belief.





(1)
      The
      Report fully complies with the requirements of Section 13(a) or 15(d) of the
      Securities Exchange Act of 1934; and





(2)
      The
      information contained in the Report fairly presents, in all material respects,
      the financial condition and results of operations of the Company.








/s/
      Barent W.
      Cater


Barent
      W.
      Cater, President and Chief Executive Officer


Dated:
      August 20, 2007
§ 358.710 Active ingredients for the control of dandruff, seborrheic dermatitis, or psoriasis. The active ingredient of the product consists of any of the following within the specified concentration established for each ingredient: ( a ) *Active ingredients for the control of dandruff.* ( 1 ) Coal tar, 0.5 to 5 percent. When a coal tar solution, derivative, or fraction is used as the source of the coal tar, the labeling shall specify the identity and concentration of the coal tar source used and the concentration of the coal tar present in the final product.
( 2 ) Pyrithione zinc, 0.3 to 2 percent when formulated to be applied and then washed off after brief exposure.
( 3 ) Pyrithione zinc, 0.1 to 0.25 percent when formulated to be applied and left on the skin or scalp.
( 4 ) Salicylic acid, 1.8 to 3 percent.
( 5 ) Selenium sulfide, 1 percent.
( 6 ) Selenium sulfide, micronized, 0.6 percent.
( 7 ) Sulfur, 2 to 5 percent.
( b ) *Active ingredients for the control of seborrheic dermatitis.* ( 1 ) Coal tar, 0.5 to 5 percent. When a coal tar solution, derivative, or fraction is used as the source of the coal tar, the labeling shall specify the identity and concentration of the coal tar source used and the concentration of the coal tar present in the final product.
( 2 ) Pyrithione zinc, 0.95 to 2 percent when formulated to be applied and then washed off after brief exposure.
( 3 ) Pyrithione zinc, 0.1 to 0.25 percent when formulated to be applied and left on the skin or scalp.
( 4 ) Salicylic acid, 1.8 to 3 percent.
( 5 ) Selenium sulfide, 1 percent.
( c ) *Active ingredients for the control of psoriasis.* ( 1 ) Coal tar, 0.5 to 5 percent. When a coal tar solution, derivative, or fraction is used as the source of the coal tar, the labeling shall specify the identity and concentration of the coal tar source used and the concentration of the coal tar present in the final product.
( 2 ) Salicylic acid, 1.8 to 3 percent.
[56 FR 63568, Dec. 4, 1991, as amended at 59 FR 4001, Jan. 28, 1994]
**Exhibit 32.1**

 

**CERTIFICATION PURSUANT TO**

**18 U.S.C. SECTION 1350,**

**AS ADOPTED PURSUANT TO**

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

The undersigned officer ofSpescom Software Inc. (the “Company”) hereby certifies to his knowledge thatthe Company’s quarterly report on Form 10-Q for the period ended June 30, 2004(the “Report”), as filed with the Securities and Exchange Commission on thedate hereof, fully complies with the requirements of Section 13(a) or 15(d), asapplicable, of the Securities Exchange Act of 1934, as amended, and that theinformation contained in the Report fairly presents, in all material respects,the financial condition and results of operations of the Company.  Thiscertification is provided solely pursuant to 18 U.S.C. Section 1350, as adoptedpursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not bedeemed to be a part of the Report or “filed” for any purpose whatsoever.

 
| Dated:                   | August 12,  2004 |   |   |
|--------------------------|------------------|--------|--------|
|                     |             |
| /s/ Carl  Mostert        |             |   |
| Carl Mostert             |             |
| Chief  Executive Officer |             |
|                          |                  |        |        |  |

 

 

A signed original of thiswritten statement required by Section 906 has been provided to Spescom SoftwareInc. and will be retained by Spescom Software Inc. and furnished to theSecurities and Exchange Commission or its staff upon request.

 

----
§ 520.370 Cefpodoxime tablets. ( a ) *Specifications.* ( 1 ) Each tablet contains cefpodoxime proxetil equivalent to 100 or 200 milligrams (mg) cefpodoxime.
( 2 ) Each chewable tablet contains cefpodoxime proxetil equivalent to 100 or 200 mg cefpodoxime.
( b ) *Sponsors.* See sponsors in § 510.600(c) of this chapter for uses as follows: ( 1 ) No. 017033 for use of product in paragraph (a)(1) of this section as in paragraph (c) of this section.
( 2 ) No. 054771 for use of products in paragraph (a) of this section as in paragraph (c) of this section.
( c ) *Conditions of use in dogs* — ( 1 ) *Amount.* 5 to 10 mg per kilogram (2.3 to 4.5 mg per pound) body weight daily for 5 to 7 days, or for 2 to 3 days beyond the cessation of clinical signs, up to a maximum of 28 days.
( 2 ) *Indications for use.* For the treatment of skin infections (wounds and abscesses) caused by susceptible strains of *Staphylococcus pseudintermedius*, *S. aureus*, *Streptococcus canis* (group G, beta-hemolytic), *Escherichia coli*, *Pasteurella multocida*, and *Proteus mirabilis.*
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[69 FR 52815, Aug. 30, 2004, as amended at 78 FR 5714, Jan. 28, 2013; 79 FR 28819, May 20, 2014; 80 FR 13229, Mar. 13, 2015; 82 FR 12169, Mar. 1, 2017; 88 FR 16547, Mar. 20, 2023]
* Pursuant to 5TH CIR. R. 47.5, the court has determined

that this opinion should not be published and is not precedent

except under the limited circumstances set forth in 5TH CIR.

R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

October 21, 2004

Charles R. Fulbruge III

Clerk

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

 

No. 04-50385

Conference Calendar

 

UNITED STATES OF AMERICA,

Plaintiff-Appellee,

versus

JOSE AVILES-JAIMES, also known as Jose Aviles,

Defendant-Appellant.

--------------------

Appeal from the United States District Court

for the Western District of Texas

USDC No. 1:04-CR-12-ALL-SS

--------------------

Before JOLLY, JONES, and WIENER, Circuit Judges.

PER CURIAM:*

Appealing the Judgment in a Criminal Case, Jose AvilesJaimes concedes that the arguments raised are foreclosed by

circuit precedent but seeks to preserve them for further review. 

The Government has moved for summary affirmance in lieu of filing

an appellee’s brief. The motion is GRANTED, and the judgment of

the district court is AFFIRMED.
Exhibit 31.1  CERTIFICATION  I, Gary N. Benninger, certify that:  1. I have reviewed this annual report on Form 10-K of Amerityre Corporation;  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others, particularly during the period in which this report is being prepared; and  (b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and  (c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.  5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.  Date: September 12, 2007  /s/Gary N. Benninger
Gary N. Benninger
Chief Executive Officer
§ 520.2280 Sulfamethizole and methenamine. ( a ) *Specifications.* Each tablet contains 250 milligrams of sulfamethizole and 250 milligrams of methenamine mandelate.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* Administer orally 1 tablet per 20 pounds of body weight 3 times per day until clinical signs are alleviated. To reduce the possibility of relapse, continue therapy for a week to 10 days.
( 2 ) *Indications for use.* For treatment of urinary tract infections such as cystitis, nephritis, prostatitis, urethritis, and pyelonephritis. As an aid in the management of complications resulting from surgical manipulations of the urinary tract such as removal of calculi from the bladder, in ureterostomies, and in instrumentation of the urethra and bladder.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 50 FR 13561, Apr. 5, 1985; 79 FR 28831, May 20, 2014]
NASA LogoNTRSNTRS - NASA Technical Reports ServerSearchmore_vertCollectionsAboutNewsHelpLogin Back to ResultsVortex Radiometry: Fundamental ConceptsVortex radiometers (VRs) enable communication systems to maximize data throughput by determining when to employ fade mitigation most efficiently. With this information, communication systems can optimize mitigation strategies before actual fades occur. Doing so maximizes the time over which the link is available, and therefore maximizes data throughput. This paper presents the fundamental concepts of vortex radiometry, including the creation of annular beam patterns through the use of orbital angular momentum (OAM). These concepts are simulated on a 100 Mbps (Megabits per second) GEO (Geosynchrous Earth Orbit)-to-ground Ka-Band communication link. During the simulation a noise source traverses across the link, and without VR capabilities the link is disrupted. However, when the situation is repeated with VR capabilities enabled, the antenna is able to increase receiver gain and maintain the link. VRs are uniquely suited to provide communication systems with the ability to optimize receiver parameters and maximize data throughput, making them critical to enabling next generation communication networks.Document ID20190011721Acquisition SourceGlenn Research CenterDocument TypeTechnical Memorandum (TM)AuthorsSchemmel, Peter J.*(NASA Glenn Research Center Cleveland, OH, United States)*Date AcquiredMay 8, 2019Publication DateApril 1, 2019Subject CategoryCommunications And RadarReport/Patent NumberE-19688GRC-E-DAA-TN67031NASA/TM-2019-220184Funding Number(s)WBS: 553323.04.10.09.01.01Distribution LimitsPublicCopyrightWork of the US Gov. Public Use Permitted.Technical ReviewNASA Peer CommitteeKeywordsOrbital Angular MomentumRadiometryAvailable DownloadsNameType20190011721.pdfSTIcloud_downloadcontent_copyvisibilityRelated RecordsThere are no records associated with this record.visibility_offNo Preview Available
 No Fear Act | Freedom of Information Act | Office of the Inspector General | Agency Financial ReportsNASA Web Privacy Policy and Important Notices | NASA Guidelines for Quality of InformationDisclaimers, Copyright, Terms of Use | Accessibility | NASA OCIO | USA.gov | NASA.govContact Us | Site MapSTI LogoNASA Official: JoAnne R. Calhoun Site Curator: STI Compliance and Distribution Services Last Modified: September 12, 2024
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
BALANCE SHEETS AND CONSOLIDATED STATEMENTS OF OPERATIONS AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>                     <C>
<PERIOD-TYPE>                   YEAR                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997             DEC-31-1996
<PERIOD-START>                             JAN-01-1997             JAN-01-1996
<PERIOD-END>                               DEC-31-1997             DEC-31-1996
<CASH>                                      16,667,209              10,094,909
<SECURITIES>                                         0                       0
<RECEIVABLES>                               15,142,094              10,424,818
<ALLOWANCES>                                   610,000                 385,000
<INVENTORY>                                          0                       0
<CURRENT-ASSETS>                                     0                       0
<PP&E>                                       4,504,932               2,543,367
<DEPRECIATION>                               1,241,154                 692,557
<TOTAL-ASSETS>                             125,067,124             157,698,429
<CURRENT-LIABILITIES>                                0                       0
<BONDS>                                              0                       0
<PREFERRED-MANDATORY>                                0                       0
<PREFERRED>                                  1,575,000               1,575,000
<COMMON>                                    14,044,891              14,032,491
<OTHER-SE>                                   6,271,205               4,276,551
<TOTAL-LIABILITY-AND-EQUITY>               125,067,124             157,698,429
<SALES>                                     19,108,132              93,613,257
<TOTAL-REVENUES>                            19,108,132             104,539,302
<CGS>                                                0              82,922,839
<TOTAL-COSTS>                                        0              82,922,839
<OTHER-EXPENSES>                            10,791,629              13,053,972
<LOSS-PROVISION>                             2,821,451               2,242,292
<INTEREST-EXPENSE>                           2,031,877               2,457,619
<INCOME-PRETAX>                              3,463,175               3,862,580
<INCOME-TAX>                                 1,343,000               1,545,000
<INCOME-CONTINUING>                          2,120,175               2,317,580
<DISCONTINUED>                                       0                       0
<EXTRAORDINARY>                                      0                       0
<CHANGES>                                            0                       0
<NET-INCOME>                                 2,120,175               2,317,580
<EPS-PRIMARY>                                      .49                     .54
<EPS-DILUTED>                                      .48                     .52


</TABLE>
§ 50.54 Clinical investigations not otherwise approvable that present an opportunity to understand, prevent, or alleviate a serious problem affecting the health or welfare of children. If an IRB does not believe that a clinical investigation within the scope described in §§ 50.1 and 56.101 of this chapter and involving children as subjects meets the requirements of § 50.51, § 50.52, or § 50.53, the clinical investigation may proceed only if: ( a ) The IRB finds that the clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children; and
( b ) The Commissioner of Food and Drugs, after consultation with a panel of experts in pertinent disciplines (for example: science, medicine, education, ethics, law) and following opportunity for public review and comment, determines either: ( 1 ) That the clinical investigation in fact satisfies the conditions of § 50.51, § 50.52, or § 50.53, as applicable, or
( 2 ) That the following conditions are met: ( i ) The clinical investigation presents a reasonable opportunity to further the understanding, prevention, or alleviation of a serious problem affecting the health or welfare of children;
( ii ) The clinical investigation will be conducted in accordance with sound ethical principles; and
( iii ) Adequate provisions are made for soliciting the assent of children and the permission of their parents or guardians as set forth in § 50.55.
[66 FR 20598, Apr. 24, 2001, as amended at 78 FR 12951, Feb. 26, 2013]
Office of the Secretary 

Office of State and Local 

Government Coordination & 

Preparedness 

Washington, DC 20531 

ODP Information Bulletin 

No. 181 July 13, 2005 

TO: All State Administrative Agency Heads 

 All State Administrative Agency Points of Contact 

 Eligible Transit Agency CEOs 

 

FROM: Matt A. Mayer 

 Acting Executive Director 

SUBJECT: Increasing Improvised Explosive Detection capabilities for U.S. Mass Transit Systems 

As a result of the July 7, 2005 terror attacks on transportation assets in London, England, the Department 

of Homeland Security (DHS) has elevated the Homeland Security Advisory Alert System Level from 

Yellow to Orange for mass transit systems. In light of the heightened concerns about possible attacks on 

transit assets here in the United States, the Office of State and Local Government Coordination and 

Preparedness (SLGCP) encourages all affected states to work with their urban area and transit 

system partners to complete the development of the required Regional Transit Security Strategies 

(RTSS) as soon as possible. SLGCP is working with the Office of Justice Programs (OJP), Office of the 

Comptroller (OC) to expedite the award of FY 2005 Transit Security Grants. As the expenditure of these 

funds is tied to the submission and approval of the RTSS, the states should not wait until the August 31st

deadline to submit these plans. 

Also, in light of the July 7th attacks, transit systems that have received funds through the Fiscal Year 2003 

Urban Areas Security Initiative (UASI) Mass Transit System Security Grant Program and the Fiscal Year 

2004 UASI Grant Program should immediately review their existing improvised explosive device (IED) 

prevention and detection capabilities to determine if it is necessary to adjust their spending plans to 

address this threat. As part of this review, specific attention should be paid to the acquisition of canines 

and other technologies relevant to the prevention of attacks involving IEDs. SLGCP will expedite the 

approval of revised budgets to permit the rapid acquisition of these capabilities. 

Lastly, grant recipients are urged to review their spending activities and contact their SLGCP 

Preparedness Officer for assistance in overcoming any barriers to the obligation, expenditure and draw 

down of these funds. For more information on the authorized use of grant funds for IED prevention and 

detection, or to request assistance with problems encountered in the expenditure of grant funds, please 

contact your SLGCP Preparedness Officer, or the SLGCP Helpline at (800) 368-6498 or 

askcsid@dhs.gov.
<PAGE>
 
                                                                    Exhibit 23.1

              CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS

We consent to the incorporation by reference in the Registration Statements
(Form S-3 No. 333-59861 and Form S-8 Nos. 333-00436 and 333-50983) pertaining to
certain shares of KeraVision, Inc. common stock issuable to the holders of
Series B convertible preferred stock, the 1997 Employee Stock Option Plan, the
1995 Director's Stock Option Plan, the 1995 Employee Stock Purchase Plan, the
1995 Stock Option Plan and the 1987 Stock Option Plan of KeraVision, Inc.  of
our report dated February 3, 1999, except for Note 9, for which the date is
March 25, 1999, with respect to the consolidated financial statements of
KeraVision, Inc. included in its Annual Report (Form 10-K) for the year ended
December 31, 1998.


San Jose, California
March 30, 1999
EXHIBIT 23



                           INDEPENDENT ACCOUNTANTS' CONSENT


             The Board of Directors
             Statewide Financial Corp.:

             We consent to incorporation by reference in the Registration
             Statements (No. 33-96844) on Form S-8, (No.3 33-09665) on
             Form S-8, (No. 333-46063) on Form S-8 and (No. 333-46065) on
             Form S-8 of our report dated January 26, 1999, relating to
             the consolidated statements of financial condition of
             Statewide Financial Corp. and subsidiary as of December 31,
             1998 and 1997 and the related consolidated statements of
             income, shareholders' equity, and cash flows for each of 
             the years in the three-year period ended December 31, 1998,
             which report appears in the December 31, 1998 Annual Report
             on Form 10-K of Statewide Financial Corp.


             KPMG LLP



             Short Hills, New Jersey
             March 26, 1999